AMPH
Price
$20.99
Change
-$0.22 (-1.04%)
Updated
Apr 22, 04:59 PM (EDT)
Capitalization
935.68M
21 days until earnings call
Intraday BUY SELL Signals
VTRS
Price
$14.52
Change
-$0.21 (-1.43%)
Updated
Apr 22, 04:59 PM (EDT)
Capitalization
16.91B
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMPH vs VTRS

Header iconAMPH vs VTRS Comparison
Open Charts AMPH vs VTRSBanner chart's image
AMPH vs VTRS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AMPH vs. VTRS commentary
Apr 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a Hold and VTRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Apr 23, 2026
Stock price -- (AMPH: $20.99 vs. VTRS: $14.52)
Brand notoriety: AMPH and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMPH: 91% vs. VTRS: 88%
Market capitalization -- AMPH: $935.68M vs. VTRS: $16.91B
AMPH [@Pharmaceuticals: Generic] is valued at $935.68M. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $16.91B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMPH’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 3 green FA rating(s).

  • AMPH’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 3 green, 2 red.
According to our system of comparison, VTRS is a better buy in the long-term than AMPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMPH’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • AMPH’s TA Score: 4 bullish, 6 bearish.
  • VTRS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than AMPH.

Price Growth

AMPH (@Pharmaceuticals: Generic) experienced а -3.18% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +4.76% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.92%. For the same industry, the average monthly price growth was +8.34%, and the average quarterly price growth was +1.81%.

Reported Earning Dates

AMPH is expected to report earnings on May 13, 2026.

VTRS is expected to report earnings on May 07, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.92% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($16.9B) has a higher market cap than AMPH($936M). VTRS has higher P/E ratio than AMPH: VTRS (236.20) vs AMPH (10.35). VTRS YTD gains are higher at: 19.406 vs. AMPH (-20.762). AMPH has higher annual earnings (EBITDA): 212M vs. VTRS (-395.4M). VTRS has more cash in the bank: 406M vs. AMPH (283M). AMPH has less debt than VTRS: AMPH (656M) vs VTRS (14.7B). VTRS has higher revenues than AMPH: VTRS (14.3B) vs AMPH (720M).
AMPHVTRSAMPH / VTRS
Capitalization936M16.9B6%
EBITDA212M-395.4M-54%
Gain YTD-20.76219.406-107%
P/E Ratio10.35236.204%
Revenue720M14.3B5%
Total Cash283M406M70%
Total Debt656M14.7B4%
FUNDAMENTALS RATINGS
AMPH vs VTRS: Fundamental Ratings
AMPH
VTRS
OUTLOOK RATING
1..100
2110
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
9367
SMR RATING
1..100
5998
PRICE GROWTH RATING
1..100
548
P/E GROWTH RATING
1..100
321
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (17) in the null industry is somewhat better than the same rating for AMPH (71) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew somewhat faster than AMPH’s over the last 12 months.

VTRS's Profit vs Risk Rating (67) in the null industry is in the same range as AMPH (93) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to AMPH’s over the last 12 months.

AMPH's SMR Rating (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for VTRS (98) in the null industry. This means that AMPH’s stock grew somewhat faster than VTRS’s over the last 12 months.

VTRS's Price Growth Rating (8) in the null industry is somewhat better than the same rating for AMPH (54) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew somewhat faster than AMPH’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as AMPH (32) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to AMPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMPHVTRS
RSI
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
45%
Momentum
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
71%
Declines
ODDS (%)
Bearish Trend 27 days ago
70%
Bearish Trend 16 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
60%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
57%
View a ticker or compare two or three
Interact to see
Advertisement
AMPH
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDVIX16.12N/A
N/A
Hartford International Equity I
PEUCX42.25N/A
N/A
Principal Equity Income C
RYBHX60.78N/A
N/A
Rydex S&P MidCap 400 Pure Growth H
ECOIX11.40N/A
N/A
Redwheel Next Generation Power InfrasIns
RTSAX45.33-0.39
-0.85%
Russell Inv Tax-Managed US Mid&Sm Cap A

AMPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMPH has been loosely correlated with AMRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMPH jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMPH
1D Price
Change %
AMPH100%
-7.42%
AMRX - AMPH
51%
Loosely correlated
-1.73%
VTRS - AMPH
46%
Loosely correlated
-0.87%
EBS - AMPH
43%
Loosely correlated
-4.19%
COLL - AMPH
42%
Loosely correlated
-2.91%
ANIP - AMPH
38%
Loosely correlated
-2.10%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with AMRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-0.87%
AMRX - VTRS
50%
Loosely correlated
-1.73%
ELAN - VTRS
46%
Loosely correlated
-4.52%
AMPH - VTRS
46%
Loosely correlated
-7.42%
EBS - VTRS
41%
Loosely correlated
-4.19%
TEVA - VTRS
38%
Loosely correlated
-2.28%
More